TrialFrontiers in immunology2026

A novel recombinant anti-cluster of differentiation 20 humanized monoclonal antibody (B001) for the treatment of neuromyelitis optica spectrum disorder: a phase 1, multicenter randomized, double-blind trial.

Dongmei Jia et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.